Hetero Labs filed an application with the Central Drugs Standard Control Organisation (CDSCO) last week. The CDSCO may soon reach out to ICMR for suggestions.
In science, establishing that something doesn’t work is as crucial as finding a solution. This is why most Covid-19 clinical trials are repurposing existing drugs.
Cipla, Hetero Labs, Jubilant Lifesciences & Mylan have now been allowed by remdesivir’s patent holder, Gilead, to produce the drug that has shown promise in Covid-19 treatment.
Under the licensing agreement, Jubilant will have the right to receive a technology transfer of the manufacturing process to scale up remdesivir production.
Drug has shown benefits in reducing recovery time for some patients, and the govt has asked companies if they’re in touch with Gilead Sciences for a licence.
Gilead Sciences plans a global consortium of pharma firms for production. It says decision of partnership will depend on how fast the drug’s supply can be ramped up.
Mini deal will likely see no cut in 10% baseline tariff on Indian exports announced by Trump on 2 April, it is learnt, but additional 26% tariffs are set to be reduced.
PTC Industries is investing Rs 1,000 cr in 4 manufacturing plants in UP, has already started supplying titanium parts to BAE Systems for its M-777 howitzers that India also uses.
Public, loud, upfront, filled with impropriety and high praise sometimes laced with insults. This is what we call Trumplomacy. But the larger objective is the same: American supremacy.
Hii I need a remdesivir 100 mg I.v